- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
Contents
What is the news?
Recently, World Health Organization (WHO) approved the Regeneron antibody combination for treatment of the novel coronavirus disease (COVID-19).
What is Regeneron?
Regeneron is a combination of two drugs — casirivimab and imdevimab.
It has reduced mortality in seronegative patients with severe infections. The drug cocktail replicates the natural antibody response of human beings. Last year it was approved by the Food and Drug Administration of the United States.
What are the recommendations of WHO regarding this therapy?
As per UN health agency, giving drugs in veins may be difficult in outpatient scenarios. For such cases, it recommended application of drugs under the skin.
Specialised clinics, adequate amounts of antibodies and trained medical staff will be required for the therapy.
Source: This post is based on the article ” COVID-19: WHO recommends Regeneron antibody therapy for high-risk & seronegative patients ” published in Down to Earth on 24th September 2021.
